Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report

By afschroeder • October 24, 2025

Le X, Baik C, Cho BC, Riess JW, Piotrowska Z, Johannes de Langen A, Goldberg SB, Goldman JW, Reguart N, Shiraishi Y, Ambrose H, Fraenkel PG, Ruiz BM, Smith PE, Tang KH, Yu HA. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. J Thorac Oncol. 2025 Oct 21:S1556-0864(25)02856-4. doi: 10.1016/j.jtho.2025.10.009. Epub ahead of print. PMID: 41130408.

Tags: Cardiology/Epi, EGFR, MET (min 3), NSCLC, Osimertinib, Publications, Savolitinib (max 5)

National Trends in Atrial Fibrillation Hospitalizations, Readmissions, and Mortality, 2010 to 2022

Khan A, Agarwal MA, Hanna P, Ziaeian B. National Trends in Atrial Fibrillation Hospitalizations, Readmissions, and Mortality, 2010 to 2022. JACC Adv. 2026 Aug 12;5(9):103118.[...]

HDL-associated proteins affecting CVD and systemic inflammation

Delk SC, Reddy ST. HDL-associated proteins affecting CVD and systemic inflammation. Curr Opin Lipidol. 2026 Aug 13. doi: 10.1097/MOL.0000000000001052. Epub ahead of print. PMID: 42578565.

Purulent Pneumococcal Pericarditis Presenting as Normotensive Cardiac Tamponade in Austrian Syndrome

Delgadillo RC, Roufeh E, Bachour K, Hanna JM. Purulent Pneumococcal Pericarditis Presenting as Normotensive Cardiac Tamponade in Austrian Syndrome. JACC Case Rep. 2026 Aug 10:109743.[...]